Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 4 August 1989:
Vol. 245. no. 4917, pp. 519 - 522
DOI: 10.1126/science.2502843
Prev | Table of Contents | Next

Articles

Science, Vol 245, Issue 4917, 519-522
Copyright © 1989 by American Association for the Advancement of Science

articles

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

JW Tetrud and JW Langston

California Parkinson's Foundation, San Jose 95128.

The effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that produces the symptoms of Parkinson's disease, can be fully prevented in experimental animals by inhibiting monoamine oxidase B. On the basis of this observation, a double-blind, placebo-controlled study in patients with early Parkinson's disease was initiated to determine whether deprenyl (a selective monoamine oxidase B inhibitor) would delay the need for L-dopa therapy by slowing the progression of the disease. Fifty-four patients were randomly assigned to deprenyl (10 mg/day) or placebo treatment groups and followed until L-dopa therapy was indicated or until the patient had been in the study for 3 years. Analysis of Kaplan-Meier survival curves for each group showed that deprenyl delayed the need for L-dopa therapy; the average time until L-dopa was needed was 312.1 days for patients in the placebo group and 548.9 days for patients in the deprenyl group. Disease progression, as monitored by five different assessment scales, was slowed (by 40 to 83% per year) in the deprenyl group compared to placebo. Therefore, early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The scientific and clinical basis for the treatment of Parkinson disease (2009).
C. W. Olanow, M. B. Stern, and K. Sethi (2009)
Neurology 72, S1-S136
   Abstract »    Full Text »    PDF »
MAO-B inhibitor know-how: Back to the pharm.
P. A. LeWitt (2009)
Neurology 72, 1352-1357
   Full Text »    PDF »
Clinical trials aimed at detecting neuroprotection in Parkinson's disease.
R. A. Hauser and T. A. Zesiewicz (2006)
Neurology 66, S58-S68
   Abstract »    Full Text »
Oxidative Stress Is Responsible for Mitochondrial Permeability Transition Induction by Salicylate in Liver Mitochondria.
V. Battaglia, M. Salvi, and A. Toninello (2005)
J. Biol. Chem. 280, 33864-33872
   Abstract »    Full Text »    PDF »
A novel formulation of selegiline for the treatment of Parkinson's disease.
J. W. Tetrud and W. C. Koller (2004)
Neurology 63, S2-S6
   Full Text »
Clinical trials of neuroprotection for Parkinson's disease.
P. A. LeWitt (2004)
Neurology 63, S23-S31
   Full Text »
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.
N. J Ives, R. L Stowe, J. Marro, C. Counsell, A. Macleod, C. E Clarke, R. Gray, and K. Wheatley (2004)
BMJ 329, 593
   Abstract »    Full Text »    PDF »
The Effect of Coenzyme Q10 Therapy in Parkinson Disease Could Be Symptomatic--Reply.
C. W. Shults, R. Haas, D. Oakes, K. Kieburtz, S. Plumb, I. Shoulson, R. Kurlan, M. F. Beal, J. Juncos, R. Watts, et al. (2003)
Arch Neurol 60, 1172-1173
   Full Text »    PDF »
The association of incident dementia with mortality in PD.
G. Levy, M.-X. Tang, E.D. Louis, L.J. Cote, B. Alfaro, H. Mejia, Y. Stern, and K. Marder (2002)
Neurology 59, 1708-1713
   Abstract »    Full Text »    PDF »
MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD.
M. A. Hernan, H. Checkoway, R. O'Brien, P. Costa-Mallen, I. De Vivo, G. A. Colditz, D. J. Hunter, K. T. Kelsey, and A. Ascherio (2002)
Neurology 58, 1381-1387
   Abstract »    Full Text »    PDF »
CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes.
M. Hidestrand, M. Oscarson, J. S. Salonen, L. Nyman, O. Pelkonen, M. Turpeinen, and M. Ingelman-Sundberg (2001)
Drug Metab. Dispos. 29, 1480-1484
   Abstract »    Full Text »    PDF »
An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment.
C. W. Olanow, R. L. Watts, and W. C. Koller (2001)
Neurology 56, S1-S88
   Full Text »    PDF »
Characterization of Extracellular Dopamine Clearance in the Medial Prefrontal Cortex: Role of Monoamine Uptake and Monoamine Oxidase Inhibition.
H. K. Wayment, J. O. Schenk, and B. A. Sorg (2001)
J. Neurosci. 21, 35-44
   Abstract »    Full Text »    PDF »
Selegiline and Parkinson's disease: It's deja vu--again.
J. W. Langston and C. M. Tanner (2000)
Neurology 55, 1770-1771
   Full Text »    PDF »
Understanding Parkinson Disease.
J. L. Cummings (1999)
JAMA 281, 376-378
   Full Text »    PDF »
Characterization of a Highly Conserved FAD-binding Site in Human Monoamine Oxidase B.
B. P. Zhou, B. Wu, S.-W. Kwan, and C. W. Abell (1998)
J. Biol. Chem. 273, 14862-14868
   Abstract »    Full Text »    PDF »
Deprenyl and Desmethylselegiline Protect Mesencephalic Neurons from Toxicity Induced by Glutathione Depletion.
C. Mytilineou, E. K. Leonardi, P. Radcliffe, E. H. Heinonen, S.-K. Han, P. Werner, G. Cohen, and C. W. Olanow (1998)
J. Pharmacol. Exp. Ther. 284, 700-706
   Abstract »    Full Text »
Brain Dopamine Neurotoxicity in Baboons Treated with Doses of Methamphetamine Comparable to Those Recreationally Abused by Humans: Evidence from [11C]WIN-35,428 Positron Emission Tomography Studies and Direct In Vitro Determinations.
V. Villemagne, J. Yuan, D. F. Wong, R. F. Dannals, G. Hatzidimitriou, W. B. Mathews, H. T. Ravert, J. Musachio, U. D. McCann, and G. A. Ricaurte (1998)
J. Neurosci. 18, 419-427
   Abstract »    Full Text »    PDF »
A 61-Year-Old Man With Parkinson's Disease.
C. W. Olanow (1996)
JAMA 275, 716-722
   Abstract »    PDF »
Selegiline in Parkinson's disease.
D. B Calne (1995)
BMJ 311, 1583-1584
   Full Text »
Flavinylation of Monoamine Oxidase B.
B. P. Zhou, D. A. Lewis, S.-W. Kwan, and C. W. Abell (1995)
J. Biol. Chem. 270, 23653-23660
   Abstract »    Full Text »    PDF »
Effect of the nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkeys.
T Aosaki, A. Graybiel, and M Kimura (1994)
Science 265, 412-415
   Abstract »    PDF »
Alzheimer's Disease and Idiopathic Parkinson's Disease Coexistence.
A. H. Rajput, B. Rozdilsky, and A. Rajput (1993)
J Geriatr Psychiatry Neurol 6, 170-176
   Abstract »    PDF »
Environmental Causation of Parkinson's Disease.
A. H. Rajput (1993)
Arch Neurol 50, 651-652
   Abstract »    PDF »
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease.
The Parkinson Study Group (1993)
N. Engl. J. Med. 328, 176-183
   Abstract »    Full Text »
Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
J. Schneider, A Pope, K Simpson, J Taggart, M. Smith, and L DiStefano (1992)
Science 256, 843-846
   Abstract »    PDF »
Oxygen Radicals and Neuropsychiatric Illness: Some Speculations.
J. B. Lohr (1991)
Arch Gen Psychiatry 48, 1097-1106
   Abstract »    PDF »
Psychiatric Effects of Selegiline.
S. J. Boyson (1991)
Arch Neurol 48, 902
   Abstract »    PDF »
Early Combination of Selegiline and Low-Dose Levodopa as Initial Symptomatic Therapy in Parkinson's Disease: Experience in 26 Patients Receiving Combined Therapy for 26 Months.
T. S. Elizan, D. A. Moros, and M. D. Yahr (1991)
Arch Neurol 48, 31-34
   Abstract »    PDF »
The Nigrostriatal Dopaminergic System Assessed In Vivo by Positron Emission Tomography in Healthy Volunteer Subjects and Patients With Parkinson's Disease.
K. L. Leenders, E. P. Salmon, P. Tyrrell, D. Perani, D. J. Brooks, H. Sager, T. Jones, C. D. Marsden, and R. S. J. Frackowiak (1990)
Arch Neurol 47, 1290-1298
   Abstract »    PDF »
Pharmacodynamic Issues Relevant to Geriatric Psychopharmacology.
B. G. Pollock, J. M. Perel, and C. F. Reynolds (1990)
J Geriatr Psychiatry Neurol 3, 221-228
   PDF »
Positron Emission Tomographic Scanning Demonstrates a Presynaptic Dopaminergic Lesion in Lytico-Bodig: The Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex of Guam.
B. J. Snow, R. F. Peppard, M. Guttman, J. Okada, W. R. W. Martin, J. Steele, A. Eisen, G. Carr, B. Schoenberg, and D. Calne (1990)
Arch Neurol 47, 870-874
   Abstract »    PDF »
A NEW THERAPY TO SLOW PROGRESSION OF PARKINSON'S.
(1989)
Journal Watch (General) 1989, 1
   Full Text »
Big first scored with nerve diseases.
R Lewin (1989)
Science 245, 467-468
   PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)